<DOC>
	<DOCNO>NCT01083394</DOCNO>
	<brief_summary>The aim study perform randomize , control trial compare percutaneous transluminal angioplasty use paclitaxel elute balloon ( PEB ) use conventional balloon treatment superficial femoral artery in-stent restenosis .</brief_summary>
	<brief_title>Paclitaxel Eluting Balloon Conventional Balloon In-Stent Restenosis Superficial Femoral Artery</brief_title>
	<detailed_description>The superficial femoral artery common place arteriosclerosis patient symptomatic low extremity vascular disease . Advances percutaneous transluminal angioplasty ( PTA ) stenting provide new option treatment disease arterial segment . Restenosis PTA occur 40-60 % within one year . A novel attempt reduce restenosis use paclitaxel elute balloon ( PEB ) . First clinical study suggest use PEBs percutaneous treatment femoropopliteal disease associate significant reduction late lumen loss target-lesion revascularization . There randomized comparison treatment patient stent restenosis superficial femoral artery . Thus , aim study compare efficacy PTA conventional balloon PEB stent restenosis SFA term reduction diameter stenosis follow-up angiogram .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Symptomatic â‰¥ 70 % instent restenosis AFS , ( Rutherford stage 26 ) Written , inform consent patient her/his legallyauthorized representative participation study Acute ischemia and/or acute thrombosis SFA Untreated ipsilateral iliac artery stenosis &gt; 70 % Not least one vessel runoff Popliteal involvement stenosis &gt; 70 % Severe renal insufficiency ( GFR &lt; 30 ml/min/m2 ) Malignancies comorbid condition ( example severe liver , renal pancreatic disease ) life expectancy le 12 month may result protocol noncompliance . Pregnancy ( present , suspected plan ) positive pregnancy test . Previous enrollment trial . Patient 's inability fully cooperate study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>PTA</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>restenosis</keyword>
</DOC>